Impact of CTLA-4 gene polymorphism on organ-specific antibody levels in patients with autoimmune thyroiditis in the Azerbaijani population

Abstract

BACKGROUND: The risk of developing immune tolerance to autoantigens in autoimmune thyroiditis is largely associated with mutations in the CTLA-4 gene, whose product negatively regulates T-cell activity.

AIM: The study aimed to investigate the +49A/G (rs231775) polymorphism of the CTLA-4 gene in patients with autoimmune thyroiditis within a sample of the Azerbaijani population and assess the impact of allele and genotype frequencies on anti-thyroperoxidase and anti-thyroglobulin antibodies.

METHODS: A study was conducted from 2021 to 2023 and included 170 patients with autoimmune thyroiditis (study group) and 65 individuals without thyroid pathology or other autoimmune diseases (control group). The sex and age of the groups were comparable. Autoimmune thyroiditis was diagnosed on the basis of medical history, assessment of thyroid status, thyroid ultrasound, and the presence of organ-specific antibodies. The results of routine thyroid function tests in the control group were within the normal range. Genotyping of the +49A/G (rs231775) polymorphism was performed by polymerase chain reaction followed by restriction fragment length polymorphism analysis using PspEI endonuclease. Quantitative variables were presented as the median (Me) and interquartile range (IQR; 25th percentile, 75th percentile). Hardy–Weinberg equilibrium for genotype frequencies was assessed using the χ² test.

RESULTS: The study revealed a statistically significant increase in the frequency of the G allele (48%) compared with the control group (33.8%; p = 0.039, χ² = 4.27, odds ratio [OR] = 1.865, 95% confidence interval [CI]: 1.028–3.382) and a decrease in the frequency of the A allele (51.2%) relative to the control group (66.1%; p = 0.0389, χ² = 4.27, OR = 0.536, 95% CI: 0.296–0.973). Anti-thyroglobulin antibody titers exceeding 100 IU/mL were detected in 22.4% of patients with the GG genotype (p = 0.005, χ² = 7.86, OR = 0.237, 95% CI: 0.088–0.635) and 55.6% of patients carrying the G allele (p = 0.0012, χ² = 10.43, OR = 0.360, 95% CI: 0.192–0.674). Anti-thyroperoxidase antibody levels ≥100 IU/mL were found in 22.7% of individuals with the GG genotype (p = 0.030) and 50.0% of those carrying the G allele (p = 0.048).

CONCLUSION: Elevated anti-thyroperoxidase and anti-thyroglobulin antibody titers were identified in individuals carrying the G allele and the homozygous GG genotype of the +49A/G polymorphism of the CTLA-4 gene in the Azerbaijani population.

Keywords

autoimmune thyroiditis / alleles / genotype / polymorphism / CTLA-4 gene / CTLA-4 gene product / autoantibodies

References

[1] Vargas-Uricoechea H. Molecular mechanisms in autoimmune thyroid disease. Cells. 2023;12(6):918. doi: 10.3390/cells12060918

[2] Vargas-Uricoechea H. Molecular mechanisms in autoimmune thyroid disease // Cells. 2023. Vol. 12, N. 6. P. 918. doi: 10.3390/cells12060918

[3] Mincer DL, Jialal I. Hashimoto thyroiditis. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459262/ Accessed: July 29, 2023.

[4] Mincer D.L., Jialal I. Hashimoto Thyroiditis. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Режим доступа: https://www.ncbi.nlm.nih.gov/books/NBK459262/ Дата обращения: 29.07.2023.

[5] Rymar OD, Pyankova AK, Maksimov VN, et al. Association of candidate gene polymorphisms for autoimmune thyroid diseases in patients with familial diffuse toxic goiter and autoimmune thyroiditis. Clinical and experimental thyroidology. 2016;12(2):46–54. (In Russ.) doi: 10.14341/ket2016246-54

[6] Рымар О.Д., Пьянкова А.К., Максимов В.Н., и др. Анализ ассоциаций полиморфизма генов-кандидатов аутоиммунных заболеваний у лиц с семейными случаями диффузного токсического зоба и аутоиммунного тиреоидита // Клиническая и экспериментальная тиреоидология. 2016. T. 12, № 2. С. 46–54. doi: 10.14341/ket2016246-54

[7] Ząbczyńska M, Polak K, Kozłowska K, et al. The contribution of IgG glycosylation to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in Hashimoto’s thyroiditis: An in vitro model of thyroid autoimmunity. Biomolecules. 2020;10:171. doi: 10.3390/biom10020171

[8] Ząbczyńska M., Polak K., Kozłowska K., et al. The contribution of IgG glycosylation to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in Hashimoto’s thyroiditis: An in vitro model of thyroid autoimmunity // Biomolecules. 2020. Vol. 10. P. 171. doi: 10.3390/biom10020171

[9] Klubo-Gwiezdzinska J, Wartofsky L. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment. Pol Arch Intern Med. 2022;132(3):16222. doi: 10.20452/pamw.16222

[10] Klubo-Gwiezdzinska J., Wartofsky L. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment // Pol Arch Intern Med. 2022. Vol. 132, N. 3. P. 16222. doi: 10.20452/pamw.16222

[11] Fröhlich E, Wahl R. Thyroid autoimmunity: Role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol. 2017:8:521. doi: 10.3389/fimmu.2017.00521

[12] Fröhlich E., Wahl R. Thyroid autoimmunity: Role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases // Front Immunol. 2017. Vol. 8. P. 521. doi: 10.3389/fimmu.2017.00521

[13] Bogner U, Schleusener H, Wall JR. Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto's thyroiditis but not Graves' disease. J Clin Endocrinol Metab. 1984;59(4):734–738. doi: 10.1210/jcem-59-4-734

[14] Bogner U., Schleusener H., Wall J.R. Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto's thyroiditis but not Graves' disease // J Clin Endocrinol Metab. 1984. Vol. 59, N. 4. P. 734–738. doi: 10.1210/jcem-59-4-734

[15] Lee HJ, Li CW, Hammerstad SS, et al. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J Autoimmun. 2015:64:82–90. doi: 10.1016/j.jaut.2015.07.009

[16] Lee H.J., Li C.W., Hammerstad S.S., et al. Immunogenetics of autoimmune thyroid diseases: A comprehensive review // J Autoimmun. 2015. Vol. 64. P. 82–90. doi: 10.1016/j.jaut.2015.07.009

[17] Li X, Qi H, Wang C, et al. Association between CTLA-4 +49a/g (rs231775) polymorphism and the risk of autoimmune thyroid diseases. А systematic review and meta-analysis. 2023. Available from: https://www.researchgate.net/publication/376578838_Association_between_CTLA-4_49AG_rs231775_polymorphism_and_the_risk_of_autoimmune_thyroid_diseases_A_systematic_review_and_meta-analysis Accessed: Jan 30, 2024.

[18] Li X., Qi H., Wang C., et al. Association between CTLA-4 +49a/g (rs231775) polymorphism and the risk of autoimmune thyroid diseases. А systematic review and meta-analysis. 2023. Режим доступа: https://www.researchgate.net/publication/376578838_Association_between_CTLA-4_49AG_rs231775_polymorphism_and_the_risk_of_autoimmune_thyroid_diseases_A_systematic_review_and_meta-analysis Дата обращения: 30.01.2024

[19] Hossen MM, Ma Y, Yin Z, et al. Current understanding of CTLA-4: From mechanism to autoimmune diseases. Front Immunol. 2023;14:1198365. doi: 10.3389/fimmu.2023.1198365

[20] Hossen M.M., Ma Y., Yin Z., et al. Current understanding of CTLA-4: From mechanism to autoimmune diseases // Front Immunol. 2023. Vol. 14. P. 1198365. doi: 10.3389/fimmu.2023.1198365

[21] Van CS, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Adv Exp Med Biol. 2020;1248:7–32. doi: 10.1007/978-981-15-3266-5_2

[22] Van Coillie S., Wiernicki B., Xu J. Molecular and cellular functions of CTLA-4 // Adv Exp Med Biol. 2020. Vol. 1248. P. 7–32. doi: 10.1007/978-981-15-3266-5_2

[23] Nusrath F, Qursheed S, Syyeda A, et al. Autoimmune thyroid patients with CTLA-4 (+49A/G) GG/AG genotypes have high seropositivity to thyroid peroxidase than thyroglobulin. Meta Gene. 2022;31:101010. doi: 10.1016/j.mgene.2022.101010

[24] Nusrath F., Qursheed S., Syyeda A., et al. Autoimmune thyroid patients with CTLA-4 (+49A/G) GG/AG genotypes have high seropositivity to thyroid peroxidase than thyroglobulin // Meta Gene. 2022. Vol. 31. P. 101010. doi: 10.1016/j.mgene.2022.101010

[25] Ebrahim E, Teklu T, Tajebe F, et al. Association of cytotoxic T-lymphocyte antigen-4 gene polymorphism with type 1 diabetes mellitus: In silico analysis of biological features of CTLA-4 protein on ethiopian population, diabetes, metabolic syndrome and obesity. Diabetes Metab Syndr Obes. 2022;15:2733–2751. doi: 10.2147/DMSO.S375023

[26] Ebrahim E., Teklu T., Tajebe F., et al. Association of cytotoxic T-lymphocyte antigen-4 gene polymorphism with type 1 diabetes mellitus: In silico analysis of biological features of CTLA-4 protein on ethiopian population, diabetes, metabolic syndrome and obesity // Diabetes Metab Syndr Obes. 2022. Vol. 15. P. 2733–2751. doi: 10.2147/DMSO.S375023

[27] Oyewole-Said D, Konduri V, Vazquez-Perez J, et al. Beyond T-cells: Functional characterization of CTLA-4 expression in immune and non-immune cell types. Front Immunol. 2020;11:608024. doi: 10.3389/fimmu.2020.60802411

[28] Oyewole-Said D., Konduri V., Vazquez-Perez J., et al. Beyond T-cells: Functional characterization of CTLA-4 expression in immune and non-immune cell types // Front Immunol. 2020. Vol. 11. P. 608024. doi: 10.3389/fimmu.2020.60802411

[29] Khalid Kheiralla KE. CTLA-4 (+49A/G) polymorphism in type 1 diabetes children of Sudanese population. Glob Med Genet. 2021;8(1):11–18. doi: 10.1055/s-0041-1723008

[30] Khalid Kheiralla K.E. CTLA-4 (+49A/G) polymorphism in type 1 diabetes children of Sudanese population // Glob Med Genet. 2021. Vol. 8, N. 1. P. 11–18. doi: 10.1055/s-0041-1723008

[31] Al-Harbi N, Abdulla M-H, Vaali-Mohammed M-A, et al. Evidence of association between CTLA-4 gene polymorphisms and colorectal cancers in Saudi patients. Genes (Basel). 2023;14(4):874. doi: 10.3390/genes14040874

[32] Al-Harbi N., Abdulla M.H., Vaali-Mohammed M.A., et al. Evidence of association between CTLA-4 gene polymorphisms and colorectal cancers in Saudi patients // Genes (Basel). 2023. Vol. 14, N. 4. P. 874. doi: 10.3390/genes14040874

[33] Rahimova RR, Dashdamirova GS, Shahverdiyeva IJ, Kerimova IA. Studying the activity of matrix metallo-proteinases and antibodies to DNA in patients with autoimmune thyroiditis. Kazan Medical Journal. 2023;104(6):851–858. doi: 10.17816/KMJ624114

[34] Рагимова Р.Р., Дашдамирова Г.С., Шахвердиева И.Д., Керимова И.А. Изучение активности матриксных металлопротеиназ и антител к ДНК у пациентов с аутоиммунным тиреоидитом // Казанский медицинский журнал. 2023. Т. 104, № 6. C. 851–858. doi: 10.17816/KMJ624114

[35] Rahimova R. Relationship between CTLA4, TNF-α and PTPN22 gene polymorphism and the serum levels of antithyroglobulin and antiperoxidase antibodies in autoimmune thyroiditis. AIMS Medical Science. 2023;10(1):14–23. doi: 10.3934/medsci.2023002

[36] Rahimova R. Relationship between CTLA4, TNF-α and PTPN22 gene polymorphism and the serum levels of antithyroglobulin and antiperoxidase antibodies in autoimmune thyroiditis // AIMS Medical Science. 2023. Vol. 10, N. 1. P. 14–23. doi: 10.3934/medsci.2023002

[37] Paterson AM, Lovitch SB, Sage PT, et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med. 2015;212(10):1603–1621. doi: 10.1084/jem.20141030

[38] Paterson A.M., Lovitch S.B., Sage P.T., et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity // J Exp Med. 2015. Vol. 212, N. 10. P. 1603–1621. doi: 10.1084/jem.20141030

[39] Patel H, Mansuri MS, Singh M, et al. Association of cytotoxic T-lymphocyte antigen 4 (CTLA4) and thyroglobulin (TG) genetic variants with autoimmune hypothyroidism. PloS ONE. 2016;11(3):e0149441. doi: 10.1371/journal.pone.0149441

[40] Patel H., Mansuri M.S., Singh M., et al. Association of cytotoxic T-lymphocyte antigen 4 (CTLA4) and thyroglobulin (TG) genetic variants with autoimmune hypothyroidism // PloS ONE. 2016. Vol. 11, N. 3. P. 0149441. doi: 10.1371/journal.pone.0149441

[41] Lo B, Zhang K, Lu W, Zheng L, et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–440. doi: 10.1126/science.aaa1663

[42] Lo B., Zhang K., Lu W., et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy // Science. 2015. Vol. 349, N. 6246. P. 436–440. doi: 10.1126/science.aaa1663

[43] Charbonnier LM, Janssen E, Chou J, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol. 2015;135(1):217–227. doi: 10.1016/j.jaci.2014.10.019

[44] Charbonnier L.M., Janssen E., Chou J., et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA // J Allergy Clin Immunol. 2015. Vol. 135, N. 1. P. 217–227. doi: 10.1016/j.jaci.2014.10.019

[45] Borysewicz-Sańczyk H, Sawicka B, Wawrusiewicz-Kurylonek N, et al. Genetic association study of IL2RA, IFIH1, and CTLA-4 polymorphisms with autoimmune thyroid diseases and type 1 diabetes. Front Pediatr. 2020;8:481. doi: 10.3389/fped.2020.00481

[46] Borysewicz-Sańczyk H., Sawicka B., Wawrusiewicz-Kurylonek N., et al. Genetic association study of IL2RA, IFIH1, and CTLA-4 polymorphisms with autoimmune thyroid diseases and type 1 diabetes // Front Pediatr. 2020. Vol. 8. P. 481. doi: 10.3389/fped.2020.00481

[47] Jin B, Wang S, Fan Z. Pathogenesis markers of Hashimoto's disease — a mini review. Front Biosci (Landmark Ed). 2022;27(10):297. doi: 10.31083/j.fbl2710297

[48] Jin B., Wang S., Fan Z. Pathogenesis markers of Hashimoto's disease — a mini review // Front Biosci (Landmark Ed). 2022. Vol. 27, N. 10. P. 297. doi: 10.31083/j.fbl2710297

RIGHTS & PERMISSIONS

Eco-Vector